Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Droplet Biosciences Inc. has four pending office actions in Biotechnology & Pharmaceuticals. Those matters are distributed among four examiners and four art units, indicating that the active portfolio reaches multiple examination channels. PRIEST, AARON A is the busiest examiner, with one pending matter, so no single examiner accounts for more than the identified share of the current activity.
The distributed assignments call for matter-by-matter prosecution management. Counsel may need to track differing examiner expectations and art-unit practices rather than rely on one uniform response approach. The profile does not identify a dominant examiner concentration, and the pending actions should be evaluated separately for claim strategy, interview planning, and response timing.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, AARON A | 1 | 61.4% | +25.6% |
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
| RAMADAN, OMAR | 1 | 25.4% | +56.5% |
| MARCETICH, ADAM M | 1 | 72.8% | +18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18435187 | DRAIN FLUIDS FOR DISEASE DIAGNOSIS AND MONITORING | PRIEST, AARON A | — |
| 18542193 | ANALYSIS OF EFFLUENT | JONES, CHRISTINE MICHELLE | — |
| 18542057 | ANALYSIS OF EFFLUENT | RAMADAN, OMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18087165 | METHODS FOR CANCER TREATMENT | MARCETICH, ADAM M | 5d |
| 18435187 | DRAIN FLUIDS FOR DISEASE DIAGNOSIS AND MONITORING | PRIEST, AARON A | — |
| 18542057 | ANALYSIS OF EFFLUENT | RAMADAN, OMAR | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1682 | 1 |
| 1678 | 1 |
| 3781 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18435187 | DRAIN FLUIDS FOR DISEASE DIAGNOSIS AND MONITORING | PRIEST, AARON A | 1681 | §102§103 | Non-Final OA | — | Pending | Feb 07, 2024 |
| 18542193 | ANALYSIS OF EFFLUENT | JONES, CHRISTINE MICHELLE | 1682 | §101§102§103§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18542057 | ANALYSIS OF EFFLUENT | RAMADAN, OMAR | 1678 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18087165 | METHODS FOR CANCER TREATMENT | MARCETICH, ADAM M | 3781 | §103 | Non-Final OA | 5d | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDroplet Biosciences Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Aaron A Priest has the most, with 1 of Droplet Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
